These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38063285)

  • 1. Cutaneous arteritis combined with antiphospholipid syndrome associated with the use of immune checkpoint inhibitors in a patient with a metastatic lung adenocarcinoma.
    Hayashi M; Shiraishi K; Yoshida S; Yatsuzuka K; Kohri N; Kuroo Y; Horie K; Muto J; Murakami M; Fujisawa Y
    J Dermatol; 2024 May; 51(5):e166-e167. PubMed ID: 38063285
    [No Abstract]   [Full Text] [Related]  

  • 2. Acquired idiopathic generalized anhidrosis following pembrolizumab treatment.
    Furuta K; Horiguchi A; Nakagawa Y; Kambe N; Kogame T
    Clin Exp Dermatol; 2022 Feb; 47(2):463-465. PubMed ID: 34610167
    [No Abstract]   [Full Text] [Related]  

  • 3. Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with
    Yue D; Qian J; Chen Z; Zhang B; Chen P; Zhang L; Li J; Zhang H; Wang C
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33558279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining immune-checkpoint inhibitors with tocilizumab to treat a lung adenocarcinoma patient with pre-existing polymyalgia rheumatica: A case report.
    Du Y; Liu XY; Zhang L
    Thorac Cancer; 2024 Jan; 15(2):198-200. PubMed ID: 38044322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy-Induced Airway Disease: A New Pattern of Lung Toxicity of Immune Checkpoint Inhibitors.
    Mitropoulou G; Daccord C; Sauty A; Pasche A; Egger B; Aedo Lopez V; Letovanec I; Beigelman-Aubry C; Nicod LP; Lazor R
    Respiration; 2020; 99(2):181-186. PubMed ID: 31914436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC.
    Tian Y; Zhai X; Yan W; Zhu H; Yu J
    Cancer Med; 2021 Jan; 10(1):3-14. PubMed ID: 33230935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).
    Vergnenegre A; Geier M; Guisier F; Lamy R; Comet B; Le Garff G; Do P; Janicot H; Morel H; Decroisette C; Andre M; Falchero L; Paleiron N; Monnet I;
    Cancer Med; 2020 Jan; 9(2):432-439. PubMed ID: 31747137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent thromboembolism, adenocarcinoma and antiphospholipid syndrome.
    Kim JS; Choi EJ
    Cerebrovasc Dis; 2002; 14(3-4):266-7. PubMed ID: 12403965
    [No Abstract]   [Full Text] [Related]  

  • 9. Bilateral lung cancer showing various responses to immune checkpoint inhibitors: A case report.
    Kodama H; Ibe T; Inoue R; Shimada T; Ishii H; Hamamoto Y
    Cancer Rep (Hoboken); 2020 Oct; 3(5):e1272. PubMed ID: 32783372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.
    Smit HJM; Aerts J; van den Heuvel M; Hiltermann TJN; Bahce I; Smit EF; Dingemans AC; Hendriks LE; Stigt JA; Schramel FMNH; van Tinteren H; Groen HJM;
    Lung Cancer; 2020 Feb; 140():107-112. PubMed ID: 31911323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors.
    Roch B; Coffy A; Jean-Baptiste S; Palaysi E; Daures JP; Pujol JL; Bommart S
    Lung Cancer; 2020 May; 143():19-26. PubMed ID: 32200137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local therapy combined with anti-PD-1 immunotherapy for advanced lung adenocarcinoma: A case report.
    Wu N; Yang X; Zhai Y; Lu W
    J Cancer Res Ther; 2024 Apr; 20(2):739-744. PubMed ID: 38687948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report.
    Tang Y; Li Y; Zhang L; Tong G; Ou Z; Wang Z; Zhang H; Qiao G
    Thorac Cancer; 2020 Apr; 11(4):1094-1098. PubMed ID: 32077636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitrs in Lung Cancer: Case Report and Literature Review.
    Xie W; Hu N; Cao L
    Front Immunol; 2021; 12():790051. PubMed ID: 34956221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variability in clinical presentation of diabetes mellitus during anti-PD-1 immunotherapy.
    Bastin M; Mosbah H; Carlier A; Boudifa A; Villemain A; Hartemann A; Andreelli F
    Diabetes Metab; 2020 Oct; 46(5):406-407. PubMed ID: 31034979
    [No Abstract]   [Full Text] [Related]  

  • 16. Atezolizumab-associated encephalitis in metastatic lung adenocarcinoma: a case report.
    Yamaguchi Y; Nagasawa H; Katagiri Y; Wada M
    J Med Case Rep; 2020 Jul; 14(1):88. PubMed ID: 32620173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onset of subacute cutaneous lupus erythematosus after the initiation of immune checkpoint inhibitor therapy of cancer.
    Gambichler T; Doerler M; Scheel CH
    Lupus; 2021 Mar; 30(3):531-533. PubMed ID: 33407044
    [No Abstract]   [Full Text] [Related]  

  • 18. A case report of neuromyelitis optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: a clinical and immunohistochemical study.
    Hirano S; Kojima A; Nakayama Y; Takeda T; Kishimoto T; Takahashi T; Kuwabara S; Mori M
    BMC Neurol; 2022 Dec; 22(1):483. PubMed ID: 36517738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.
    Sugano T; Seike M; Saito Y; Kashiwada T; Terasaki Y; Takano N; Hisakane K; Takahashi S; Tanaka T; Takeuchi S; Miyanaga A; Minegishi Y; Noro R; Kubota K; Gemma A
    Thorac Cancer; 2020 Apr; 11(4):1052-1060. PubMed ID: 32096610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Inhibitor Therapy Induces Inflammatory Activity in Large Arteries.
    Calabretta R; Hoeller C; Pichler V; Mitterhauser M; Karanikas G; Haug A; Li X; Hacker M
    Circulation; 2020 Dec; 142(24):2396-2398. PubMed ID: 32894978
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.